Δ9-Tetrahydrocannabinol Acts as a Partial Agonist to Modulate Glutamatergic Synaptic Transmission between Rat Hippocampal Neurons in Culture
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Δ 9 -Tetrahydrocannabinol (Δ 9 -THC) is the principal psychoactive ingredient in marijuana. We examined the effects of Δ 9 -THC on glutamatergic synaptic transmission. Reducing the extracellular Mg ++ concentration bathing rat hippocampal neurons in culture to 0.1 mM elicited a repetitive pattern of glutamatergic synaptic activity that produced intracellular Ca ++ concentration spikes that were measured by indo-1-based microfluorimetry. Δ 9 -THC produced a concentration-dependent inhibition of spike frequency with an EC 50 of 20 ± 4 nM and a maximal inhibition of 41 ± 3%. Thus, Δ 9 -THC was potent, but had low intrinsic activity. Δ 9 -THC (100 nM) inhibition of spiking was reversed by 300 nM N -piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide (SR 141716), indicating that the inhibition was mediated by CB1 cannabinoid receptors. Δ 9 -THC attenuated the inhibition produced by a full cannabinoid receptor agonist, (+)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl](1-napthalenyl)methanone monomethanesulfonate (Win 55212-2), indicating that Δ 9 -THC is a partial agonist. The effect of Δ 9 -THC on synaptic currents was also studied. 6-Cyano-2,3-dihydroxy-7-niroquiinoxaline (CNQX)-sensitive excitatory postsynaptic currents were recorded from cells held at −70 mV in the whole-cell configuration of the patch-clamp and elicited by presynaptic stimulation with an extracellular electrode. Win 55212-2 and Δ 9 -THC inhibited excitatory postsynaptic current (EPSC) amplitude by 96 ± 2% and 57 ± 4%, respectively. Excitatory postsynaptic current amplitude was reduced to 75 ± 5% in the presence of both drugs, demonstrating that Δ 9 -THC is a partial agonist. The psychotropic effects of Δ 9 -THC may result from inhibition of glutamatergic synaptic transmission. The modest physical dependence produced by Δ 9 -THC as well as its lack of acute toxicity may be due to the ability of the drug to reduce, but not block, excitatory neurotransmission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 2×
“molar to micromolar have been described (Devane et al., 1988; Herkenham et al., 1990).”
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586 · cited 2×
“The effects of D-THC are mediated by cannabinoid receptors that are distributed throughout the central nervous system (Herkenham et al., 1990; Tsou et al., 1998) and are present at high density on the presynaptic terminals of glutamatergic synapses (Twitchell et al.”
Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons
Twitchell, W., Brown, S., & Mackie, K. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.78.1.43 · Cited by 544
Cited by
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Based on the well-known protective effect of cannabinoids against oxidative cell damage and excitotoxicity (Hampson et al., 1998; Shen and Thayer, 1999; Abood et al., 2001; van der Stelt et al., 2001a), combined with their antispastic effect in MS, Carter and Rosen (2001) have proposed the use of…”
BackgroundPertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
The Neuroscience of Drug Reward and Addiction
Volkow, N. D., Michaelides, M., & Baler, R. (2019) · Physiological Reviews · doi:10.1152/physrev.00014.2018 · Cited by 863
Cannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Cannabinoid receptors and their ligands
Pertwee, R. G., & Ross, R. A. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0341 · Cited by 561
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
The acute effects of cannabinoids on memory in humans: a review
Ranganathan, M., & D’Souza, D. C. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0508-y · Cited by 525
Glutamatergic substrates of drug addiction and alcoholism
Gass, J. T., & Olive, M. F. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.039 · Cited by 484
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo
Jones, N. A., Hill, A. J., Smith, I., Bevan, S. A., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.159145 · Cited by 347
Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?
McPartland, J. M., & Russo, E. B. (2001) · Journal of Cannabis Therapeutics · doi:10.1300/j175v01n03_08 · Cited by 321
Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond
Pertwee, R. G. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00108.x · Cited by 314
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312
Effects of Cannabinoids on Neurotransmission
Szabo, B., & Schlicker, E. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_11 · Cited by 252
Metadata
- Authors
- Shen, M., & Thayer, S. A.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 1999-01-01
- Volume
- 55
- Issue
- 1
- Pages
- 8-13
- ISSN
- 0026-895X (ISSN-L)
- 1521-0111
- OpenAlex
- W2096203089
- Cited by
- 145
- References
- 6
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.